Jilidea (Abiraterone Acetate)

Abiraterone acetate blocks the enzyme CYP17, which is essential for converting steroid precursors into androgens. By inhibiting this step, the drug dramatically reduces the production of testosterone and other androgens from the adrenal glands, testes and tumor tissue, depriving prostate cancer cells of the hormones they need to proliferate.

The exact dosage of Jilidea is determined by the prescribing physician based on the patient’s clinical condition, weight, and other medications. Typically, the regimen involves a daily oral dose taken with food, but the prescriber sets the precise amount and schedule for each individual.

Safety of abiraterone acetate in pregnancy and lactation has not been established. It is generally contraindicated for pregnant or nursing women because it can interfere with fetal development and hormone balance. Women of child‑bearing potential should use effective contraception during treatment.

To order Jilidea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, oncology centres, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

The primary alternative to abiraterone acetate is enzalutamide, another antiandrogen used in metastatic castration‑resistant prostate cancer. While both lower androgen signaling, abiraterone works upstream by blocking androgen synthesis, whereas enzalutamide blocks the androgen receptor. Choice between them depends on patient tolerance, comorbidities, drug‑interaction profile and physician preference.

Jilidea should be stored at room temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Jilidea is taken orally as a tablet, usually once daily and preferably with food to enhance absorption. It is commonly co‑prescribed with a low‑dose glucocorticoid such as prednisone to counteract mineralocorticoid excess caused by CYP17 inhibition.

The most serious adverse events include adrenal insufficiency, severe hypertension, hepatic failure, and cardiac arrhythmias. Patients should be monitored regularly for blood pressure spikes, liver‑function abnormalities, electrolyte disturbances, and signs of cortisol deficiency, and any severe symptoms should prompt immediate medical evaluation.

Jilidea is contraindicated in patients with severe hepatic impairment, uncontrolled hypertension, known hypersensitivity to abiraterone acetate or any excipients, and those receiving strong CYP3A4 inducers that could reduce efficacy. Caution is also advised for individuals with a history of adrenal insufficiency or significant cardiac disease.